Press release
In Depth Research on Global Breast Cancer Monoclonal Antibodies Market Outlook 2020
" Global Breast Cancer Monoclonal Antibodies Market Outlook 2020" Report Highlights:* Breast Cancer Monoclonal Antibodies Mechanism
* Global Breast Cancer Monoclonal Antibody Market Analysis
* Breast Cancer Monoclonal Antibodies Pipeline by Company & Phase
* Breast Cancer Monoclonal Antibodies Pipeline: 62 mAb
* Majority Breast Cancer Monoclonal Antibodies in Preclinical Phase: 17 mAb
* Marketed Breast Cancer Monoclonal Antibodies: 6 mAb
For Report Sample Contact: neeraj@kuickresearch.com
Report Weblink:https://www.kuickresearch.com/report-Global-Breast-Cancer-Monoclonal-Antibodies-Market-Outlook-2020.php
Table of Contents
1. Introduction to Monoclonal Antibodies
1.1 History of Development of Monoclonal Antibodies
1.2 Working of Monoclonal Antibodies
2. Need for Monoclonal Antibodies for Cancer Treatment
3. Breast Cancer Monoclonal Antibodies Mechanism
4. Global Breast Cancer Monoclonal Antibody Market Analysis
4.1 Current Market Scenario
4.2 Breast Cancer Pipeline Overview
5. Global Breast Cancer Monoclonal Antibody Market Dynamics
5.1 Favorable Market Parameters
5.2 Commercialization Challenges
6. Global Breast Cancer Monoclonal Antibodies Market Future Prospects
7. Breast Cancer Monoclonal Antibodies Pipeline by Company & Phase
7.1 Unknown
7.2 Research
7.3 Preclinical
7.4 Clinical
7.5 Phase I
7.6 Phase I/II
7.7 Phase II
7.8 Phase III
7.9 Registered
8. Marketed Breast Cancer Monoclonal Antibodies Clinical Insight
8.1 Bevacizumab (Avastin®)
8.2 Pertuzumab (Omnitarg, Perjeta®)
8.3 Trastuzumab (Herceptin®)
8.4 Trastuzumab Biosimilar (Hertraz™ & CANMAb™)
8.5 Trastuzumab Emtansine (Kadcyla®)
8.6 Trastuzumab Subcutaneous (Herceptin®)
9. Discontinued & Suspended Breast Cancer Monoclonal Antibodies Pipeline by Company & Phase
9.1 Discontinued
9.2 No Development Reported
10. Competitive Landscape
10.1 Amgen
10.2 Biocad
10.3 Biocon
10.4 Celltrion Pharm
10.5 CuraGen Corporation
10.6 Dyax Corp
10.7 GlaxoSmithKline
10.8 ImmunoGen
10.9 MacroGenics
10.10 Merck
10.11 Merrimack Pharmaceuticals
10.12 Novartis
10.13 Pierre Fabre
10.14 Pfizer
10.15 Recombio
10.16 Roche Holding
10.17 Samsung Bioepis
10.18 Synthon
Figure 1-1: History of Development of Monoclonal Antibodies
Figure 1-2: Working of Monoclonal Antibodies
Figure 3-1: Mechanism of Bevacizumab
Figure 3-2: Mechanism of Denosumab
Figure 3-3: Mechanism of Trastuzumab
Figure 3-4: Mechanism of Trastuzumab Emtansine
Figure 3-5: Mechanism of Pertuzumab
Figure 4-1: Breast Cancer Monoclonal Antibodies Pipeline by Phase (%), 2015
Figure 4-2: Breast Cancer Monoclonal Antibodies Pipeline by Phase (Numbers), 2015
Figure 4-3: No Development Reported Breast Cancer Monoclonal Antibodies Pipeline by Phase (%), 2015
Figure 4-4: No Development Reported Breast Cancer Monoclonal Antibodies Pipeline by Phase (Numbers), 2015
Figure 4-5: Discontinued Breast Cancer Monoclonal Antibodies Pipeline by Phase (%), 2015
Figure 4-6: Discontinued Breast Cancer Monoclonal Antibodies Pipeline by Phase (Numbers), 2015
Figure 5-1: Global Breast Cancer Monoclonal Antibody Market Favorable Parameters
Figure 5-2: Breast Cancer Monoclonal Antibodies Commercialization Challenges
Figure 10-1: Amgen Clinical Pipeline
Figure 10-2: Biocon Clinical Pipeline
Figure 10-3: Celltrion Clinical Pipeline
Figure 10-4: MacroGenics Clinical Pipeline
Figure 10-5: Novartis Clinical Pipeline
Figure 10-6: Synthon Clinical Pipeline
Table 2-1: Breast Cancer Monoclonal Antibodies Available in Global Market
Table 2-2: Herceptin Biosimilars Available in Global Market
Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.
Neeraj Chawla
neeraj@kuickresearch.com
KuicK Research
L29 - L34, First Floor
Block L,Connaught Place
New Delhi-110001
India
+91-11-47067990
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release In Depth Research on Global Breast Cancer Monoclonal Antibodies Market Outlook 2020 here
News-ID: 753619 • Views: …
More Releases from Kuick Resarch
![Bispecific Antibody Drug Conjugates Development](https://cdn.open-pr.com/L/8/L823408304_g.jpg)
Bispecific Antibody Drug Conjugates Development
The development of bispecific antibody drug conjugates (ADCs) marks a significant advancement in the field of targeted cancer therapy. These innovative molecules combine the specificity of bispecific antibodies with the powerful cytotoxic effects of drug conjugates, creating a new class of therapeutic agents that hold great promise for treating complex and resistant cancers. The process of developing these ADCs involves intricate design, engineering, and testing to ensure their safety, efficacy,…
![Breakthroughs in KRAS Inhibitor Research](https://cdn.open-pr.com/L/7/L726713982_g.jpg)
Breakthroughs in KRAS Inhibitor Research
KRAS mutations have posed a significant challenge in oncology for decades, but recent breakthroughs in KRAS inhibitor research have sparked hope for new cancer therapies. KRAS is a key regulator of cell growth and survival, and its mutations are prevalent in various cancers, particularly lung, colorectal, and pancreatic cancers. Despite being one of the most sought-after targets, KRAS has been notoriously difficult to inhibit, earning the reputation of being "undruggable."
Download…
![Lumakras Drug Clinical Insight and Sales Forecast 2026](https://cdn.open-pr.com/V/5/V520536611_g.jpg)
Lumakras Drug Clinical Insight and Sales Forecast 2026
"Lumakras Drug Clinical Insight and Sales Forecast 2026" Report Highlights:
* NSCLC Targeting Lumakras Market Opportunity (US$ Million)
* Colorectal Cancer Targeting Lumakras Market Opportunity (US$ Million)
* Pharmacokinetics of Lumakras (Sotorasib)
* Dosage, Patent and Price Analysis
* Lumakras Ongoing Clinical Trials
* Global KRAS Protein Inhibitors Clinical Trials
Download Report: https://www.kuickresearch.com/report-lumakras-sotorasib-sales-forecast-fda-approved-kras-inhibitor-clinical-trials-non-small-cell-lung-cancer-nslc-g12c-mutation-c30h30f2n6o3-ras-gtpase
The rising burden of cancer and the increasing cancer mortality rates possesses an unmet need for the development of novel therapies in the management…
![Global EZH2 Inhibitor Market Opportunity, Sales and Clinical Trials Insight 2026](https://cdn.open-pr.com/V/5/V520839233_g.jpg)
Global EZH2 Inhibitor Market Opportunity, Sales and Clinical Trials Insight 2026
"Global EZH2 Inhibitor Market Opportunity, Sales and Clinical Trials Insight 2026" Report Highlights:
* Global EZH2 Inhibitor Market Opportunity > US$ 1.2 Billion by 2026
* Tazverik (Tazemetostat) First Approved EZH2 Inhibitor Drug
* Dosage, Price and Sales Analysis of Tazverik
* Tazverik Sales Opportunity > US$ 900 Million by 2026
* Tazverik Sales Forecast 2021 Till 2026
* EZH2 Inhibitor Clinical Pipeline Overview By Company, Indication and Phase
* EZH2 Inhibitor in Clinical Trials: 7 Drugs
Download…
More Releases for Monoclonal
Impact COVID-19 on Monoclonal Antibodies Market 2021 Generated Opportunities for …
Different monoclonal antibodies with unique mechanism of actions have been approved over the past few years, which work on immune checkpoints such as CTLA-4, PD-1, and PD-L1. Manufacturers are focusing on developing drugs belonging to various classes in order to treat variety of diseases ranging from cancer to rare diseases. Monoclonal antibody coupled with chemotherapy agents is becoming a viable treatment option to treat various cancers. For instance, in 2017,…
Monoclonal Antibodies Market Outline and Updates..!!
Rising adoption of strategies such as acquisition, collaboration, and license agreement by the market players is expected to bolster the monoclonal antibodies market growth over the forecast period. For instance, in 2018, F. Hoffman-La Roche AG and Kymab Group Ltd entered into a clinical trial agreement to evaluate KY1044 (product of Kymab Group), a human monoclonal antibody, for the treatment of solid tumors. Also, in 2018, Novartis AG entered into…
Global Monoclonal Antibody Diagnostic Reagents Market
Antibodies are an essential tool for many applications including flow cytometric analysis, immunoprecipitation, enzyme-linked immunosorbent assay (ELISA), immunocytochemistry, western blotting, and immunohistochemistry. Moreover, monoclonal antibodies (MAbs) are significant diagnostic reagent used in microbiological research, biomedical research, and also in diagnosis of various diseases such as HIV, hepatitis, herpes simplex, influenza infections, chlamydia, as well as for the treatment of cancer. Therefore, due to its importance in the clinical application, it…
Monoclonal Antibody Custom Service Market Ravishing Growth with CAGR of 10.84% | …
Complete Study of Monoclonal Antibody Custom Service Market Research Report is added on MarketResearchFuture.com with Latest Advancement. Detail analysis on possible segments and sub segments of the market. Along with this regional analysis of the market which includes North America, Europe, Asia Pacific and Middle East and Africa.
Avail Premium Sample Copy @ https://www.marketresearchfuture.com/sample_request/4515
Monoclonal Antibody Custom Service Market – Overview
It is estimated that monoclonal antibody custom service market is expected to…
Global Monoclonal Antibodies Pipeline Analysis
The market for monoclonal antibodies (mAB) has become the fastest growing segment of the pharmaceutical industry. In 2012, there were more than 30 monoclonal antibody therapies approved by the FDA which generated annual sales of more than US$ 40 Billion. As the therapeutic mABs already play a significant part in effective medical treatment, it is most likely that their importance would increase by manyfolds in the future.
There has been a…
Global Cancer Monoclonal Antibodies Pipeline Analysis
In the past few years monoclonal antibodies have emerged as a therapeutic modality for cancer. These monoclonal antibodies are designed to selectively target cancer cells and extract various responses, thus indirectly protecting the non cancerous cells. This characteristic of monoclonal antibodies coupled with increasing potential of the oncology market has made many pharmaceutical giants to invest a significant portion of their R&D on cancer monoclonal antibodies.
In recent years the popularity…